The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - A meta-regression analysis

European Journal of Heart Failure

Volumn 4, Issue 4, 2002, Pages 515-529

  Thackray, Simon ^a   Easthaugh, Joanne ^b   Freemantle, Nick ^b   Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adrenergic pathway; Heart failure; Intravenous inotropic drugs; Meta analysis

Indexed keywords

AMRINONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DOBUTAMINE; DOPAMINE; DOPEXAMINE; ENOXIMONE; INOTROPIC AGENT; MILRINONE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; TOBORINONE; CARDIOTONIC AGENT;

ADRENERGIC ACTIVITY; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EMBASE; HEART FAILURE; HEMODYNAMICS; HUMAN; INOTROPISM; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; OUTCOMES RESEARCH; OUTPATIENT; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; ARTICLE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036673089     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00041-7     Document Type: Review

References (73)

1. Brown A, Cleland JGF. Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J 1995;19:1063-9.
2. Remme WJ, Cleland JGF, et al. European Society of Cardiology Guidelines for the management of heart failure. Eur Heart J 1997;18:736-53.
3. Anonymous. Guidelines for the evaluation and management of heart failure. Report on the ACC/AHA taskforce practice guidelines. Circulation 1995, 92, 2764-84.
4. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States, time for a different approach? J Heart Lung Transplant 1993;13:107-12.
5. Packer M, Cohn J. Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardiol Jan 21, 1999.
6. Caldicott LD, Hawley K, Heppell R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after myocardial infarction: a randomised double-blind trial. Eur Heart J 1993;14:696-700.
7. Seino Y, Momomura SI, Takano T, Hayakawa H, Katoh K. Multcenter, double-blind study of milrinone for patients with acute heart failure in Japan. Crit Care Med 1996;9:1490-7.
8. Tuttle RR, Mills J. Dobutamine: development of a new caatecholamine to selectively increase cardiac contractility. Circ Res 1975;36:185.
9. Sonneblick EH, Frishman WH. Dobutamine: a new synthetic cardio-selective sympathetic amine. N Engl J Med 1979;300:17.
10. Ross J. Adrenergic regulation of the force-frequency effect. Basic Res Cardiol 1998;93:95-101. Suppl 1.
11. MacGregor DA, Butterworth JF, Zaloga CP, Prielipp RC, James R, Royster RL. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994;106(3):835-41. Sep.
12. Lewin RF, Davidson E, Zafrir N, Strasberg B, Sclarovsky S, Hellman C, Agmon J. Short- and long-term doubutamine treatment in chronic ischemic heart failure. Clin Cardiol 1987;10(6):335-9. Jun.
13. Ruffollo RR, Spardlin TA, Pollock GD. Alpha and Beta adrenergic effects of the stereo isomers of dobutamine. J Pharmacol Exp Ther 1981;219:447.
14. Unverforth DV, Blaunford M, Kates RE, Leier CV. Tolerance to Dobutamine after a 72 h continuous infusion. Am J Med 1980;69:262-6.
15. Bohm M, et al. Reduction in Beta receptor density and evaluation of positive inotropic responses in diseased myocardium. Eur Heart J 1988;9:844-52.
16. Cohn JN. Plasma Norepinephrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984;311:819-23.
17. Ter Wee PM. Effect of IV infusion of dopamine on renal function in normal individuals and those with renal disease. Am J Nephrol 1986;6:42-6.
18. Baldwin L, Henderson A, Hickman P. Effect of postoperative low-dose Dopamine on renal function after elective major vasculaar surgery. Ann Intern Med 1994;120:744-74.
19. Francis GS, Sharma B, Hodges M. Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse. Am Heart J 1982;103(6):995-1000.
20. Gollub SB, Elkayam U, Young JB, Miller LW, Haffey KA, et al. Efficacy and safety of a short-term (6-h) intravenous infusion of dopexamine in patients with severe congestive heart failure: a randomized, double-blind, parallel placebo- controlled multicenter study. J Am Coll Cardiol 1991;18:383-90.
21. Tan LB, Littler WA, Murray RG. Comparison of the haemodynamic effects of dopexamine and dobutamine in patients with severe congestive heart failure. Int J Cardiol 1991;30(2):203-8. Feb.
22. Bayliss J, Thomas L, Poole-Wilson P. Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: comparison with dobutamine, captopril and nitrate. J Cardiovasc Pharmacol 1987;9(5):551-4.
23. LeJemtel TH. Amrinone: A new cardiotonic agent in the treatment of intractable cardiac failure in man. Circulation 1979;59:1098-104.
24. Alousi AA, Johnson DC. The pharmacology of the bipyridines: amrinone and milrinone. Circulation 1986 73, 3, Pt2 III10-24.
25. Scholz H, Meyer W. Phosphodiesterase inhibiting properties of the newer inotropes. Circulation 1986;73(suppl 3):99-108.
26. Anderson JL, Baim DS, Fein SA, Goldstein RA, Lejemtel T, Likoff MJ. Efficacy and safety of sustained (48 h) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. J Am Coll Cardiol 1987;9:711-22.
27. Atallah G, George M, Lehot JJ, et al. Arythmies chez les patients en bas débit cardiaque apprés chirugie valvulaire: Étude randomisée, aveugle et comparative dobutamine vs. énoximone. Achr Mal Cœur Vaiss 1990;83:63-8.
28. Biddle TL, Benotti JR, Creager MA, et al. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 1987;59:1345-50.
29. Butterworth JF, Royster RL, Prielipp RC, Lawless ST, Wallenhaupt SL. Amrinone in cardiac surgical patients with left ventricular dysfunction. A prospective, randomized, placebo-controlled trial. Chest 1993;104:1660-7.
30. Young JB. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia? Pharmacotherapy 1996;16:78S-84S. (2 Pt 2).
31. DiBianco R, Shabetai R, et al. Comparison of oral milrinone, digoxin and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
32. Hoit BD, Burwig S, Eppert D, Bhat G, Walsh RA. Effect of a novel inotropic agent (OPC-18790) on systolic and diastolic function in patients with severe heart failure. Am Heart J 1994;128:1156-63.
33. Carroll JD, Lang RM, Neumann AL, Borow KM, Rajfer SI. The differential effects of positive inotropes and vasodilator therapy on diastolic function in patients with congestive cardiomyopathy. Circulation 1986;74(4):815-25.
34. Monrad ES, et al. Improvement in indexes of diastolic function in patients with congestive heart failure treated with milrinone. Circulation 1984;70:1030-7.
35. Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep 2001;3(3):224-31.
36. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trial. JAMA 1995;273:408-12.
37. Fleiss J, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer. A critique. J Clin Epidemiol 1991;44:127-39.
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
39. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:2685-99.
40. Carlin JB. Meta Analysis for 2x2 tables: A Bayesian approach. Stat Med 1992;11:141-58.
41. Hardy RJ, Thompson SG. A likelihood approach to meta analysis with random effects. Stat Med 1996;15:619-29.
42. Spiegelhalter DJ, Thomas A, Best NG, Gilks W.R. BUGS: Bayesian inference Using Gibbs Sampling. Version 0.50. Cambridge: MRC Biostatistics Unit, 1995.
43. Ioannidis JPA, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS defining illness. Ann Intern Med 1995;122:856-66.
44. Freemantle N, Mason JM, Eccles M. Deriving treatment recommendations from evidence within randomised trials: the role and limitation of meta analysis. Int J Technol Assess Health Care. In press.
45. Silke B, Verma SP, Midtbo KA, Reynolds G, Taylor SH. Comparative haemodynamic dose-response effects of dobutamine and amrinone in left ventricular failure complicating acute myocardial infarction. J Cardiovasc Pharmacol 1987;9:19-25.
46. Rich MW, Woods ML, Davila-Roman VG, et al. A randomized comparison of intravenous amrinone vs. dobutamine in older patients with decompensated congestive heart failure. J Am Geriatr Soc 1995;43:271-4.
47. Marcus RH, Raw K, Patel J, Bitha A, Sareli P. Comparison of intravenous amrinone and dobutamine in congestive heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1990;66:1107-12.
48. Karlsberg RP, DeWood MA, DeMaria AN, Berk MR, Lasher KP. For the Milrinone-Dobutamine Study Group. Clin Cardiol 1996;19:21-30.
49. Adamopoulos S, Piepoli M, Qiang F, et al. Effects of pulsed β-stimulant therapy on β-adrenoceptors and chronotropic responsiveness in chronic heart failure. Lancet 1995;345:344-9.
50. DICE Collaborative Group. Ambulatory intermittent 6-month low-dose Dobutamine infusion in severe heart failure: DICE multicenter trial. J Am Coll Cardiol 1997; 326A.
51. Dies F, Krell MJ, Whitlow P et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986; (Abstracts) 74: Supp II (152).
52. Ellis A, Bental T, Kimchi O, Ravid M, Lishner M. Intermittent dobutamine treatment in patients with chronic heart failure: a randomized, double-blind, placebo-controlled study. Clin Parmacol Ther 1998;63:682-5.
53. Erlemeier H, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure: long-term effects and lack of tolerance. Cardiovasc Drugs Ther 1992;6:391-8.
54. Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB. Sustained improvement of cardiac function in patients with congestive heart failure after short term infusion of dobutamine. Circulation 1984;69:113-9.
55. Hsueh CW, Lee WL, Chen CK, et al. Dopamine and dobutamine have different effects on heart rate variability in patients with congestive heart failure. Chin Med J (Tapei) 1998;61:199-209.
56. Galinier M, Rochiccioli JP, Edouard P, et al. Comparaison énoximone/dobutamine dans l'insuffisance cardiaque congestive chronique décompensée en bas débit. Arch Mal Coeur Vaiss 1990;83:27-32.
57. Caldicott LD, Hawley K, Heppell R, Woodmansey PA, Channer KS. Intravenous enoximone or dobutamine for severe heart failure after myocardial infarction: a randomized double-blind trial. Eur Heart J 1993;14:696-700.
58. Asanoi H, Sasayama S, Sakurai T, et al. Intravenous dopexamine in the treatment of acute congestive heart failure: results of a multicentre, double-blind, placebo-controlled withdrawal study. Cardiovasc Drugs Ther 1995;9:791-7.
59. Machii T, Yokota M, Nagata K, Ishihara H, Iwase M, Sobue T. Effect of dobutamine and OPC-18790 on diastolic chamber stiffness in patients with idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 1997;29:265-72.
60. Young JB. Evolving concepts in the treatment of heart failure: should new inotropic agents carry promise or paranoia?. Pharmacotherapy 1996;16:78S-84S. (2 Pt 2).
61. Sasayama S. What do the newer inotropic drugs have to offer? Cardiovasc Drugs Ther Feb 1992;6(1):15.
62. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of Oral Milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
63. Packer M, Leir CV. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 1987;75:55-63. (Suppl IV).
64. Thackray S, Coletta A, Jones P, Dunn A, Clark AL, Cleland JGF. Clinical trials update: Highlights of the scientific sessions of heart failure 2001, a meeting of the Working Group on heart failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail 2001;3:491-4.
65. Jones CG, Cleland JGF. Meeting report- the LIDO, HOPE, MOXCON and WASH studies. Eur J Heart Fail 1999;1:425-31.
66. Gomes UC, Cleland JG. Heart Failure Update. Eur J Heart Fail 1999;1:301-2.
67. Cleland JGF, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol. In press.
68. Karlsberg RP, Cryer PE, Roberts RR. Serum plasma catecholamine response early in the course of myocardial infarction. Relation to infarct extent and mortality. Am Heart J 1981;102:24-9.
69. Lindenfield J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectively at low doses of carvedilol. Ann Pharmacother 1999;33(12):1266.
70. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation 1996;94(11):2817-25.
71. Flesch M, Ettelbruck S, Rosenkranz S, et al. Differential effects of carvedilol and metoprolol on isoprenaline-induced changes in beta-adrenoceptor density and systolic function in a rat cardiac myocytes. Cardiovasc Res 2001;49(2):371-80.
72. Gilbert EM, Port JD. Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure. Curr Cardiol Rep 2000;2(3):225-32.
73. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone vs. dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001;81:141.